SAN DIEGO, Jan. 12, 2016 /PRNewswire/ -- Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today its oncology genomics program, including the development of comprehensive whole germline and tumor genome analysis, as well as tumor and germline exome analysis products.
"As part of HLI's mission to tackle some of the most troubling diseases that limit our healthy lifespans, we have obviously been focused on cancer. There is a strong need for a new and cost-effective cancer genome product because most insurance companies aren't generally covering these kinds of tests. We believe our science and technology should offer more informed treatment options for a large number of patients and their physicians," said J. Craig Venter, Ph.D., Co-founder and CEO, HLI.
With HLI's comprehensive whole germline and cancer genome product, a patient's germline is sequenced to 30x coverage and compared to their tumor genome which will be sequenced to 90x coverage. The team employs RNASeq technology on tumors to understand the expression of mutated genes, and ImmunoSeq to sequence the patient's T cell repertoire. HLI is also testing liquid biopsy technology to detect circulating free tumor DNA and circulating tumor cells.
The output of the sequencing efforts is a fully annotated genome report on all findings for patients and their clinicians which compares the patient's cancer genome to the germline genome. The analysis provides insight into the tumor mutations which can guide treatment decisions including immunotherapy, targeted molecular therapies and also other clinical trials that might be of value to the patient. The whole germline analysis identifies variants which may have predisposed the individual to certain types of cancer.
Dr. Venter will be outlining the HLI oncology program in San Francisco, CA at the J.P. Morgan 34th Annual Healthcare Conference in an 11:30 a.m. PT presentation.
About Human Longevity, Inc.™
Human Longevity, Inc. (HLI) is the genomics-based, technology-driven company creating the world's largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine. HLI's business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information please visit, http://www.humanlongevity.com or http://www.healthnucleus.com.
SOURCE Human Longevity, Inc.